SG10202012080UA - Method of treating liver fibrosis - Google Patents
Method of treating liver fibrosisInfo
- Publication number
- SG10202012080UA SG10202012080UA SG10202012080UA SG10202012080UA SG10202012080UA SG 10202012080U A SG10202012080U A SG 10202012080UA SG 10202012080U A SG10202012080U A SG 10202012080UA SG 10202012080U A SG10202012080U A SG 10202012080UA SG 10202012080U A SG10202012080U A SG 10202012080UA
- Authority
- SG
- Singapore
- Prior art keywords
- liver fibrosis
- treating liver
- treating
- fibrosis
- liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345086P | 2016-06-03 | 2016-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202012080UA true SG10202012080UA (en) | 2021-01-28 |
Family
ID=60479090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810602YA SG11201810602YA (en) | 2016-06-03 | 2017-06-02 | Method of treating liver fibrosis |
| SG10202012080UA SG10202012080UA (en) | 2016-06-03 | 2017-06-02 | Method of treating liver fibrosis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810602YA SG11201810602YA (en) | 2016-06-03 | 2017-06-02 | Method of treating liver fibrosis |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10682344B2 (en) |
| EP (1) | EP3463350B1 (en) |
| JP (2) | JP2019517523A (en) |
| KR (1) | KR102444366B1 (en) |
| CN (2) | CN115154467A (en) |
| AU (1) | AU2017274521B2 (en) |
| BR (1) | BR112018074452A2 (en) |
| CA (1) | CA3025671A1 (en) |
| ES (1) | ES2966111T3 (en) |
| IL (1) | IL263245B (en) |
| MX (1) | MX2018014743A (en) |
| RU (1) | RU2740902C2 (en) |
| SG (2) | SG11201810602YA (en) |
| WO (1) | WO2017210526A1 (en) |
| ZA (1) | ZA201807992B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment for modulating gut microbiota |
| CN115154467A (en) * | 2016-06-03 | 2022-10-11 | 坎莫森特里克斯公司 | Methods of treating liver fibrosis |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| JP7369033B2 (en) * | 2016-11-10 | 2023-10-25 | ガルメド リサーチ アンド ディベロップメント リミテッド | Treatment of fibrosis |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| PT3600309T (en) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Therapeutic combinations for treating liver diseases |
| BR112019025659A2 (en) | 2017-06-05 | 2020-08-25 | Viking Therapeutics, Inc. | compositions for the treatment of fibrosis |
| AU2018326785B2 (en) | 2017-09-03 | 2023-03-02 | Angion Biomedica Corp. | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
| CN111630047B (en) | 2018-02-02 | 2023-05-23 | 四川科伦博泰生物医药股份有限公司 | Benzazepine compounds containing carboxylic acid groups, and preparation method and application thereof |
| AU2019287679B2 (en) * | 2018-06-12 | 2022-04-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
| WO2020037023A1 (en) * | 2018-08-14 | 2020-02-20 | Avolynt | Method for treating primary sclerosing cholangitis |
| US20220016137A1 (en) * | 2018-12-05 | 2022-01-20 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN113302190A (en) | 2019-01-15 | 2021-08-24 | 吉利德科学公司 | FXR (NR1H4) modulating compounds |
| AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
| US11091467B2 (en) | 2019-05-08 | 2021-08-17 | Aligos Therapeutics, Inc. | Modulators of THR-β and methods of use thereof |
| MX2022000802A (en) * | 2019-07-30 | 2022-02-16 | Kobiolabs Inc | Kit for predicting or diagnosing nonalcoholic fatty liver disease, and method for diagnosing nonalcoholic fatty liver disease. |
| CN114245743B (en) * | 2019-07-30 | 2023-12-08 | Ko生物技术有限公司 | Compositions and methods for preventing, alleviating or treating liver injury |
| CN114929214A (en) * | 2019-11-22 | 2022-08-19 | 阿沃林特有限公司 | Application of SGLT2 inhibitor in treatment of primary biliary cholangitis |
| CN113274368B (en) * | 2020-02-20 | 2023-08-22 | 甘莱制药有限公司 | Pharmaceutical composition for treating steatohepatitis and preparation method thereof |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20240115545A1 (en) * | 2020-10-08 | 2024-04-11 | Curome Biosciences Co., Ltd. | Pharmaceutical composition containing b-lapachone as active ingredient for prevention or treatment of cholestatic liver disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118578A1 (en) * | 2004-05-26 | 2005-12-15 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| CA2594726C (en) | 2005-01-14 | 2013-03-19 | Chemocentryx, Inc. | Heteroaryl sulfonamides and ccr2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20070219245A1 (en) | 2006-03-14 | 2007-09-20 | Cuifen Hou | Method of use for substituted dipiperidine ccr2 antagonists |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| CN101511800B (en) * | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | Triazolyl phenyl benzenesulfonamides |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| KR101849560B1 (en) * | 2007-07-12 | 2018-04-17 | 케모센트릭스, 인크. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation |
| PE20100156A1 (en) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | NAFLD TREATMENT |
| CN102239180B (en) * | 2008-08-18 | 2014-12-31 | 辉瑞大药厂 | Antibodies to CCR2 |
| RS53555B1 (en) | 2009-12-17 | 2015-02-27 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists and uses thereof |
| WO2012114223A1 (en) * | 2011-02-25 | 2012-08-30 | Pfizer Limited | A method of treating liver fibrosis |
| WO2013040316A1 (en) * | 2011-09-16 | 2013-03-21 | Galectin Therapeutics, Inc. | Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| WO2013167554A1 (en) * | 2012-05-09 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| TWI696462B (en) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | The therapeutic agent for nonalcoholic fatty liver disease |
| EP3777863A1 (en) * | 2014-09-12 | 2021-02-17 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| CN115154467A (en) * | 2016-06-03 | 2022-10-11 | 坎莫森特里克斯公司 | Methods of treating liver fibrosis |
-
2017
- 2017-06-02 CN CN202210819034.8A patent/CN115154467A/en active Pending
- 2017-06-02 EP EP17807548.7A patent/EP3463350B1/en active Active
- 2017-06-02 ES ES17807548T patent/ES2966111T3/en active Active
- 2017-06-02 AU AU2017274521A patent/AU2017274521B2/en active Active
- 2017-06-02 BR BR112018074452-2A patent/BR112018074452A2/en unknown
- 2017-06-02 MX MX2018014743A patent/MX2018014743A/en unknown
- 2017-06-02 WO PCT/US2017/035628 patent/WO2017210526A1/en unknown
- 2017-06-02 CA CA3025671A patent/CA3025671A1/en active Pending
- 2017-06-02 KR KR1020187037797A patent/KR102444366B1/en active IP Right Grant
- 2017-06-02 RU RU2018145459A patent/RU2740902C2/en active
- 2017-06-02 SG SG11201810602YA patent/SG11201810602YA/en unknown
- 2017-06-02 SG SG10202012080UA patent/SG10202012080UA/en unknown
- 2017-06-02 US US15/612,124 patent/US10682344B2/en active Active
- 2017-06-02 JP JP2018563453A patent/JP2019517523A/en not_active Withdrawn
- 2017-06-02 CN CN201780048523.5A patent/CN109475537A/en active Pending
-
2018
- 2018-11-25 IL IL263245A patent/IL263245B/en unknown
- 2018-11-26 ZA ZA2018/07992A patent/ZA201807992B/en unknown
-
2020
- 2020-05-06 US US16/867,956 patent/US11357760B2/en active Active
-
2022
- 2022-05-11 US US17/662,979 patent/US20220313668A1/en active Pending
- 2022-11-30 JP JP2022191906A patent/JP7431931B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102444366B1 (en) | 2022-09-19 |
| KR20190026687A (en) | 2019-03-13 |
| RU2018145459A (en) | 2020-07-09 |
| RU2018145459A3 (en) | 2020-07-09 |
| JP2019517523A (en) | 2019-06-24 |
| US20200268727A1 (en) | 2020-08-27 |
| AU2017274521A1 (en) | 2018-12-13 |
| ES2966111T3 (en) | 2024-04-18 |
| US10682344B2 (en) | 2020-06-16 |
| SG11201810602YA (en) | 2018-12-28 |
| IL263245B (en) | 2021-09-30 |
| CN115154467A (en) | 2022-10-11 |
| EP3463350B1 (en) | 2023-09-13 |
| BR112018074452A2 (en) | 2019-03-19 |
| IL263245A (en) | 2018-12-31 |
| AU2017274521B2 (en) | 2021-08-19 |
| ZA201807992B (en) | 2023-10-25 |
| JP2023022227A (en) | 2023-02-14 |
| JP7431931B2 (en) | 2024-02-15 |
| US20220313668A1 (en) | 2022-10-06 |
| MX2018014743A (en) | 2019-04-11 |
| WO2017210526A1 (en) | 2017-12-07 |
| US20170348293A1 (en) | 2017-12-07 |
| CN109475537A (en) | 2019-03-15 |
| EP3463350A1 (en) | 2019-04-10 |
| US11357760B2 (en) | 2022-06-14 |
| EP3463350A4 (en) | 2020-01-29 |
| RU2740902C2 (en) | 2021-01-21 |
| CA3025671A1 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263245B (en) | Method of treating liver fibrosis | |
| HRP20181692T1 (en) | Treatment of fibrosis | |
| IL260539B (en) | Method of treating c3 glomerulopathy | |
| IL281293A (en) | Methods of treating hyperalgesia | |
| IL256207B (en) | Methods of treating multiple sclerosis | |
| HK1245657A1 (en) | Method of preventing or treating hearing loss | |
| EP3440107A4 (en) | Method of treating atherosclerosis | |
| EP3556389A4 (en) | Method for preventing and treating liver fibrosis | |
| EP3445450A4 (en) | Method of treating or preventing liver conditions | |
| GB201904142D0 (en) | Improved method of FT-IMS | |
| HK1244692A1 (en) | Methods of treating fibrosis | |
| ZA201804380B (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| EP3091972A4 (en) | Method of treating liver disorders | |
| GB2554032B (en) | Method of Coating | |
| HUE062013T2 (en) | Method for treating surfaces of wooden materials | |
| GB201602802D0 (en) | Method of treatment | |
| EP3139912A4 (en) | Method of treating idiopathic pulmonary fibrosis | |
| SG11201710199PA (en) | Methods of treating multiple sclerosis | |
| EP3148523A4 (en) | Method of inhibiting or treating fibrosis | |
| AU2016901494A0 (en) | Method of treating or preventing liver conditions | |
| GB201511017D0 (en) | Method of treatment |